(Reuters) – The European Union’s health regulator said on Friday it had recommended granting marketing authorization for Amicus Therapeutics Inc’s experimental combination therapy to treat a muscle disorder called Pompe disease.
(Reporting by Khushi Mandowara; Editing by Krishna Chandra Eluri)
